Compare Neurocrine Biosciences Inc (NBIX) vs iShares Silver Trust (SLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs iShares Silver Trust — how do they compare? Neurocrine Biosciences Inc trades at $141.09 (market cap $14.36B), while iShares Silver Trust trades at $54.5 (market cap $29.02B). The key difference: iShares Silver Trust is far larger — about 2× Neurocrine Biosciences Inc's market cap, and iShares Silver Trust is more actively traded (16,510,334 versus 1,237,180). Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and iShares Silver Trust for 89 Days on average.
| NBIX | SLV | |
|---|---|---|
Market Cap | $14.36B | $29.02B |
Volume | 1,237,180 | 16,510,334 |
Sector | Health | — |
52-Week High | $185.50 | $105.57 |
52-Week Low | $123.10 | $42.40 |
Typical Hold Time | 23 Days | 89 Days |
Enterprise Value | $14.37B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a 20.91% net income margin and consistent earnings beats, including a Q2 2026 EPS of $2.85 versus $1.85 expected. Recent news highlights pipeline advancements in Prader-Willi syndrome and active participation in investor conferences. Key support is at $142, with resistance at $145.
The outlook is positive, driven by robust product growth, particularly from Ingrezza and Crenessity, and a deep pipeline. Risks include pricing pressures on Ingrezza by 2029 and execution challenges in portfolio expansion. Analyst consensus is strongly bullish with a $204.18 price target, suggesting significant upside from current levels.
SLV (iShares Silver Trust) is trading at $53.82, down 2.94% with a bearish technical outlook. The ETF shows minimal operational activity with $0 revenue but generated $2.17M net income in 2024. Technical indicators show strong bearish momentum with 13 sell signals from moving averages, though RSI suggests potential oversold conditions. Recent news highlights silver's volatility amid Fed policy uncertainty and Treasury yield fluctuations.
Outlook remains cautious as silver faces pressure from rising rates and dollar strength. The ETF's structure provides pure silver exposure but carries metal price volatility risks. Near-term direction depends on Fed policy clarity and industrial demand trends, with technical support at $53-54 levels offering potential entry points for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About iShares Silver Trust
The ETF seeks to reflect such performance before payment of the ETF's expenses and liabilities. It is not actively managed. The ETF does not engage in any activities designed to obtain a profit from, or to ameliorate losses caused by, changes in the price of silver.
Read more on SLV →
